Thomas Cannell, Sesen Bio CEO
Sesen Bio reaches deal with investor group, paving way for Carisma merger
With a new deal, Sesen Bio’s merger with CAR-M player Carisma Therapeutics is finally getting the signal to move forward.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
